Astellas Collaborates with Concerto HealthAI on Real-World Evidence (RWE) Initiative for Acute Myeloid Leukemia (AML)


  • Astellas partners with Concerto HealthAI to uitilize Concerto’s RWD in order to track the response in patients with FLT3 mutation-positive r/r AML  
  • The companies will utilize ASCO’s CancerLinQ Discovery database of de-identified cancer patient records to improve understanding of responses in patients, AML treatment patterns, disease progression and opportunities for improved QoL
  • The CancerLinQ is a platform designed to monitor, coordinate and improve cancer outcomes with collection, aggregation, curation and analysis of data. Concerto HealthAI and CancerLinQ exclusive collaborated to advance critical research and improve outcomes in multiple cancers

Click here to read full press release/ article | Ref: Astellas | Image: Chemistry World